Still, despite the lower incidence of AF associated with newer-generation BTKis compared to ibrutinib, Tarnowski et al. found that ibrutinib and acalabrutinib showed comparable effects on calcium handling in cultured myocytes treated with IGF-1, reducing the calcium transient amplitude and slowing its decay [22]. Here, IGF1 is linked to atrial fibrillation.